In a bid to gain access to a costly AIDS drug sold by ViiV Healthcare, Kazakhstan officials may go to court and pursue a compulsory license, the latest dispute in which a cash-strapped government is considering sidestepping patents in order to provide medicines to its citizens.
At issue is a blockbuster treatment called dolutegravir that is sold under the Tivicay brand name by the company, which is actually a venture largely controlled by GlaxoSmithKline (GSK), although Pfizer (PFE) and Shionogi have small stakes. ViiV was formed a decade ago to concentrate on developing HIV and AIDS drugs, which have regularly been a flashpoint in the global debate over access to medicines.
And so it would seem, holiday weekend or not, the ‘gate to the Pharmalot’ is always open. Interesting development, mr ed, with more to come, I’m sure.
Comments are closed.